| Time | Session |
|---|
|
5:45 p.m.
6:45 p.m.
|
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
WCN24-AB-847, Poster Board= MON-296
Jonathan Barratt
Poster Presenter
|
VALIDITY OF RENAL DOPPLER RESISTIVITY INDEX IN RENAL ALLOGRAFT INFECTION
WCN24-AB-769, Poster Board= MON-297
|
MYELOMA KIDNEY: A RARE ENTITY IN PATIENTS IN THE FIFTH DECADE OF LIFE RELATING TO A CASE AND REVIEW OF THE LITERATURE.
WCN24-AB-1793, Poster Board= MON-298
Alejandra Galvan Ruiz
Poster Presenter
|
The clinical and health economic effect of a 6-month physical activity digital health intervention on health-related quality of life in people with chronic kidney disease
WCN24-AB-1556, Poster Board= MON-299
|
EPIDEMIOLOGICAL PROFILE OF KDIGO STAGE III ACUTE KIDNEY INJURY WITH THE NEED FOR RENAL SUPPORT THERAPY IN THE INTENSIVE CARE UNIT: OUR EXPERIENCE
WCN24-AB-2582, Poster Board= MON-300
|
COMPARING HORSE VS RABBIT ATG AS INDUCTION THERAPY IN KIDNEY TRANSPLANT
WCN24-AB-2364, Poster Board= MON-301
Pavan Kumar Rao Navva
Poster Presenter
|
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
WCN24-AB-1506, Poster Board= MON-302
Dana Rizk
Poster Presenter
|
Predicting the risks of kidney failure and death in adults with moderate-to-severe chronic kidney disease (KDpredict)
WCN24-AB-2729, Poster Board= MON-303
Pietro Ravani
Poster Presenter
|
UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS
WCN24-AB-762, Poster Board= MON-304
James Tumlin
Poster Presenter
|